Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 20, Number 2—February 2014

Research

Human Antibody Responses to Avian Influenza A(H7N9) Virus, 2013

Li Guo1, Xi Zhang1, Lili Ren1, Xuelian Yu1, Lijuan Chen1, Hongli Zhou, Xin Gao, Zheng Teng, Jianguo Li, Jiayu Hu, Chao Wu, Xia Xiao, Yiyi Zhu, Quanyi Wang, Xinghuo Pang, Qi Jin2, Fan Wu2, and Jianwei Wang2Comments to Author 
Author affiliations: MOH Key Laboratory of Systems Biology of Pathogens, Beijing, People’s Republic of China (L. Guo, L. Ren, J. Li, Q. Jin, J. Wang); Institute of Pathogen Biology, Beijing (L. Guo, L. Ren, H. Zhou, X. Gao, J. Li, C. Wu, X. Xiao, Q. Jin, J. Wang); Shanghai Municipal Center for Disease Control and Prevention, Shanghai, People’s Republic of China (X. Zhang, X. Yu, Z. Teng, J. Hu, Y. Zhu, F. Wu); Beijing Municipal Center for Disease Control and Prevention, Beijing (L. Chen, Q. Wang, X. Pang)

Main Article

Figure 3

Association between antibody responses against H7 and seasonal subtypes in patients infected with influenza A(H7N9) virus, China. A) Levels of IgG against H1 and H3 in serum samples after symptom onset. IgG in samples taken at acute-phase (≤7 days), convalescent-phase (17–37days,) and 102–125 days after symptom onset were titrated by ELISA with recombinant H1 and H3 hemagglutinin antigens, respectively. IgG titers were transformed to log10. Bars indicate SE. B and C) Correlation between IgG agai

Figure 3. Association between antibody responses against H7 and seasonal subtypes in patients infected with influenza A(H7N9) virus, ChinaA) Levels of IgG against H1 and H3 in serum samples after symptom onsetIgG in samples taken at acute-phase (≤7 days), convalescent-phase (17–37days,) and 102–125 days after symptom onset were titrated by ELISA with recombinant H1 and H3 hemagglutinin antigens, respectivelyIgG titers were transformed to log10Bars indicate SEB and C) Correlation between IgG against H3 (B) and H1 (C) in acute-phase serum and against H7 in convalescent-phase serum**p<0.01.

Main Article

1These authors contributed equally to this article and are co–first authors.

2These authors contributed equally to this article and are co–senior authors.

TOP